BAT Launches Virtual R&D Visitor Experience

Apr.07.2022
BAT Launches Virtual R&D Visitor Experience
BAT launches virtual visitor experience showcasing cutting-edge research and development activities in various scientific fields.

January 19, 2022

 

BAT has launched a new virtual visitor experience that allows guests to "walk through" the company's research and development laboratories, meet top scientists, and view the results of new research. Tourists have the opportunity to explore the company's scientific methods and progress in reducing tobacco harm, as well as showcasing R&D activities in important and emerging fields such as biology, chemistry, toxicology, sensory science, aerosol analysis, product safety, consumer insights, and plant biotechnology. This underscores BAT's commitment to science in reducing the impact of its business on health and providing a better tomorrow. TMBAT has created a virtual R&D visitor experience, an online tour of its global R&D center located in Southampton, UK, allowing people to explore its cutting-edge science and innovation.

 

Experience is built on a foundation of the best available technology, open and transparent scientific methods, which support the reduction of risk in product portfolios and beyond nicotine activities. The company regularly welcomes visitors to its global research center, with over 3,500 people seeing the facilities firsthand since 2011. However, with travel greatly reduced, virtual experiences allow people from around the world to access and understand BAT's scientific research, reduce tobacco harm reduction (THR) activities, and gain insights and perspectives from experts.

 

David O'Reilly, PhD, the Director of scientific research at BAT, emphasized the importance of research and development as the foundation of their work. By prioritizing science and research, they have made significant progress in developing new product categories that have undergone rigorous testing and scientific validation as reduced-risk alternatives to traditional tobacco products. Their research is heavily influenced by consumer preferences and continually incorporates evolving scientific and innovative developments into their products. This approach allows them to offer a range of enjoyable, reduced-risk alternatives to cigarettes while maintaining very high safety and quality standards.

 

Our new virtual visitor experience showcases the breadth of science we are conducting and the strong scientific framework we are using to evaluate and support our products in reducing tobacco harm.

 

A virtual visitor experience has been developed, offering a one-stop center for people who wish to learn about the science behind BAT. This includes a tour through the 360-degree lab, animations, videos, scientist profiles and podcasts. The aim of this initiative is to highlight BAT's commitment in building a better future while reducing its impact on public health. BAT invests nearly £350 million annually to find innovative ways to reduce its influence on public health and aims to have 50 million non-combustible product consumers by 2030.

 

BAT conducts research in a wide range of scientific fields including molecular biology, toxicology, and chemistry, driving constant innovation and learning, and establishing the company as an industry leader.

 

Visitors who take a tour of the research and development virtual experience will be able to explore:

 

Sensory Science: This specialized department helps BAT better understand consumer product experiences and decodes them into actionable insights to support product and brand development. Biotech Laboratory: BAT scientists utilize their specialized knowledge in whole-genome sequencing, metabolomics, and computational biology to provide enhanced consumer experiences. These teams also grow plants and identify sustainable compound sources. Biology Laboratory: Scientists test BAT's new category products for potential impacts on human cells compared to cigarette smoke. Battery Laboratory: The facility revolutionizes the design, development, and testing of BAT's rechargeable devices. The batteries undergo rigorous speed tests to ensure they meet high-quality standards.

 

Original link:

 

British American Tobacco (BAT) has launched a virtual research and development visitor experience, showcasing world-class science behind their next-generation reduced-risk† nicotine products.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
The U.S. Food and Drug Administration has revised the rules under Import Alert 98-07 to incorporate its May 2026 enforcement-priority policy for certain electronic nicotine delivery systems marketed without premarket authorization. The alert continues to allow detention without physical examination, or DWPE, for ENDS lacking required marketing authorization, while directing field divisions to apply the May risk-based framework. When necessary, detention or refusal decisions must also undergo review by the FDA's Center for Tobacco Products. Products including PACHA and Vuse Pro have already emerged as industry examples of the May policy, although enforcement discretion does not constitute FDA marketing authorization.
News
Sep.28 by 2Firsts Perspectives
JTI Proposes 25-Cent Irish Cigarette Tax Increase, Says It Could Raise €45 Million
JTI Proposes 25-Cent Irish Cigarette Tax Increase, Says It Could Raise €45 Million
Japan Tobacco International's Irish business has proposed a €0.25 tax increase on a pack of 20 cigarettes in its pre-Budget 2027 submission, below the €0.50-or-more increases typically imposed in recent Irish budgets. JTI says the proposal could generate around €45 million in additional Exchequer revenue while limiting further movement toward illicit and non-Irish-tax-paid tobacco. Revenue's existing estimate for a comparable €0.25 increase, including pro-rata rises on other tobacco products, is about €18 million for a full year.
JTI
Sep.18 by 2Firsts Perspectives
Zhang Xiaotang Appointed Deputy Director of China’s Tobacco Regulator, Adding Another Finance-Background Official to Top Leadership
Zhang Xiaotang Appointed Deputy Director of China’s Tobacco Regulator, Adding Another Finance-Background Official to Top Leadership
China’s State Council has appointed Zhang Xiaotang as deputy director of the State Tobacco Monopoly Administration, with the regulator’s official website now listing him as a Party leadership group member and deputy director. Zhang previously led Hebei China Tobacco and earlier headed the STMA’s finance and audit department. His appointment follows the elevation earlier this year of former tax official Yao Laiying to head the STMA, adding another senior official with a strong fiscal or financial-management background to China Tobacco’s top leadership in 2026.
News
Sep.20
PMI CEO Attends Opening of IQOS Global Flagship in Tokyo’s Ginza as 1,814 Limited ILUMA i PRIME Sets Launch
PMI CEO Attends Opening of IQOS Global Flagship in Tokyo’s Ginza as 1,814 Limited ILUMA i PRIME Sets Launch
IQOS opened its first global flagship, IQOS Flagship Ginza, in Tokyo on September 4, 2026, replacing the former IQOS Store Ginza after nearly a decade of operation. The new location expands conventional product retail into member lounges, digital experiences, art installations and brand programming. IQOS also launched a Ginza-exclusive IQOS ILUMA i PRIME set limited to 1,814 individually numbered units, priced at JPY11,980, or about US$77. PMI Sales Strategy Consultant Yuji M. later said on LinkedIn that more than 500 people had lined up from the night before the opening.
Sep.07
As FDA Reshapes PMTA Reviews and ENDS Enforcement Priorities, CTP Acting Director Bret Koplow to Keynote NATO Event for a Retail Network of 66,000-Plus Stores
As FDA Reshapes PMTA Reviews and ENDS Enforcement Priorities, CTP Acting Director Bret Koplow to Keynote NATO Event for a Retail Network of 66,000-Plus Stores
Bret Koplow, acting director of the U.S. Food and Drug Administration's Center for Tobacco Products, will deliver a keynote and participate in a fireside chat at the National Association of Tobacco Outlets' Sept. 29-30 conference in Washington. His appearance comes months after the FDA moved to accelerate PMTA reviews and introduced a more differentiated enforcement policy for certain unauthorized ENDS and oral nicotine pouch products. The agency also plans a public list identifying manufacturers and products it does not currently intend to prioritize for enforcement under the May guidance. NATO says its membership includes more than 66,000 retail stores, making product-status transparency and enforcement boundaries directly relevant to the retail sector.
Aug.14
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08